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AH  antigen  was  detected  during  our  initial  analysis  of  the  humoral  immune 
response of melanoma patients to autologous melanoma cells (I). Serum from patient 
AH was found to react with a  cell surface antigen expressed by cultured autologous 
melanoma cells, but not by autologous skin fibroblasts or peripheral blood lympho- 
cytes. Absorption tests indicated that AH antigen was expressed by some allogeneic 
melanoma cell lines, but not by any other normal or malignant cell types examined 
(1). An antigen with related properties was found during a  comparable study of the 
autologous reactivity of sera from patients  with astrocytoma  (2).  This  antigen,  A  J, 
was expressed by all astrocytoma cell lines and a  high proportion of melanoma cell 
lines, but was not detected on cultured fibroblasts or epithelial cancers. Comparison 
of the AJ  and AH  phenotypes of a  series of melanoma cell  lines  showed only two 
phenotypes, AJ+/AH + or AJ-/AH-,  suggesting a  serological relatedness of AH  and 
AJ antigens. Of the 75 patients with melanoma that have been analyzed for autologous 
reactivity, <5%  have had demonstrable AH antibody in their sera (3).  Overt cancer 
is not  a  prerequisite  for the presence of AH  antibody,  because  sera  from 6  of  106 
normal individuals were also found to have AH reactivity  (4).  In the present report, 
we summarize the results of typing an extensive panel  of human cell  types  for AH 
antigen and provide evidence that the AH determinant is related to GD2 ~ ganglioside. 
Materials and Methods 
Cells and  Tissues.  The  derivation and  maintenance of melanoma and other cell lines are 
described in refs.  1, 2, 4-6. Noncuhured cells from autopsy specimens were prepared by finely 
mincing the specimen in RPMI  1640 medium supplemented with penicillin (100 IU/ml) and 
streptomycin  (100  #g/ml);  the  resulting cell suspension was  washed  repeatedly  in  the same 
medium before use. 
Reference Gangliosides.  The source of purified gangliosides are given in ref.  7.  GD2, isolated 
from adult brain (8, 9), was generously provided by Dr.  R. K. Yu, Yale University School of 
Medicine, New Haven, CT. Gnlb and Gwlb were purchased from Seromed Co., Munich, Federal 
Republic of Germany. GDa and GM4 were isolated from SK-MEL-28 cells and chicken brain, 
respectively, in our laboratory. 
Isolation  of Gangliosides from SK-MEL-13  Melanoma  Cell Line.  Packed  SK-MEL-13 cells (10 
ml) were extracted sequentially with 30 vol of chloroform/methanol (C/M)  (2:1,  1:1,  and  1:2). 
The sample was filtered, evaporated, and resuspended in 50 ml of C/M  (2:1), and glycolipids 
were precipitated at  --20°C with  10 vol of acetone. Acidic glycolipids were isolated from this 
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fraction by Florisil  and DEAE-Sephadex chromatography (see ref.  7). Individual gangliosides 
were isolated by silica gel chromatography. The sample (1 ml) was applied to a column (60 × 
1  cm)  of  Iatrobeads  (Iatron  Chemical  Co.,  Tokyo,  Japan)  equilibrated  in  n-propanol: 
NH4OH:H20, (60:9.5:11.5)  (solvent  1). Gangliosides were eluted with the same solvent, and 
400-pl  fractions were collected after discarding the first  10 ml of the eluate. Gangliosides were 
detected by applying aliquots of the fractions to an activated silica gel plate (Rediplates; Fisher 
Scientific Co., Pittsburgh, PA), and the plates were developed in solvent 1 and visualized with 
resorcinol-HCl. 
SerologicalAssays.  The immune adherence (IA) assay was performed as described (1, 2, 4, 5). 
Qualitative and quantitative absorption tests were done according to procedures developed in 
our past  work (1,  2, 4, 5, 6).  Glycolipid inhibition tests  were performed as described in  (7). 
Diluted AH serum was mixed with 50 /~g of the acidic glycolipid fraction; the mixture was 
incubated for 30 min at  room temperature and 30 min on ice and assayed for residual AH 
antibody. Purified gangliosides and SK-MEL-13 ganglioside fractions were tested in the same 
manner. 
Results 
Reactivity of AH Serum with  Autologous and Allogeneic Melanoma Cell  Lines.  Fig.  1 
illustrates the reaction of AH serum with AH melanoma cells (SK-MEL- 13) and three 
other  melanoma  cell  lines.  Tests  with  these  and  other  cell  lines  showed  that  cells 
reacting  with  AH  serum  in  direct  tests  absorbed  the  reactivity  of AH  serum  for 
autologous SK-MEL-13 cells, whereas direct test-negative cells did not absorb autolo- 
gous AH reactivity. One of the AH  + cell lines, SK-MEL-31, showed higher reactivity 
with  AH sera  than  did  autologous SK-MEL-13 melanoma cells  (Fig.  1).  Although 
this could have been caused by contaminating antibodies in AH sera, this proved not 
to be the case; preabsorption of AH sera with skin fibroblasts from the same donor as 
SK-MEL-31  did  not  lower reactivity for SK-MEL-31,  and  quantitative  absorption 
tests indicated that SK-MEL-31 had > 10 times more AH antigen than AH melanoma. 
Because  of this  higher  sensitivity  to  AH  antibody,  SK-MEL-31,  rather  than  AH 
melanoma, was used as the target cell in subsequent absorption and inhibition tests. 
AH Phenotype of Normal and Malignant Human Cells.  Table I summarizes the results 
of absorption tests with  a  panel  of human cell  types. AH expression  is  restricted  to 
cells of neuroectodermal origin:  melanoma,  astrocytoma, neuroblastoma,  fetal,  and 
adult brain. The presence of AH on chondrosarcomas is an unexpected exception to 
this pattern. In a  series of 44 melanoma cell lines, 30 typed AH  + and  14 typed AH-. 
Biochemical Characterization of AH Antigen.  The fact that  AH antigenicity was not 
destroyed by trypsin,  Pronase, formaldehyde (0.33%), or heating  (100°C  for 5  min) 
suggested that  AH antigen  might be a  glycolipid. Consequently, neutral  and acidic 
glycolipids were isolated  from AH  + SK-MEL-13 cells and  tested  for AH inhibitory 
activity.  Acidic  glycolipids  were  inhibitory,  whereas  neutral  glycolipids  had  no 
detectable effect. The acidic glycolipid fraction from a  series of AH  + and AH-  cells 
and  tissues  was  subsequently  tested  (Table  I).  Fractions  from  AH  +  sources  were 
inhibitory, whereas fractions from AH- sources were not inhibitory. Partial purifica- 
tion of AH antibody-reactive ganglioside from SK-MEL-13 cells was carried out by 
Florisil, DEAE-Sephadex, and Iatrobead chromatography. Fig. 2 A shows the pattern 
of gangliosides  eluted  from  the  Iatrobead  column.  GM3  (fractions  86-98)  and  GD3 
(fractions 99-122)  are the major gangliosides of SK-MEL-13, as they were found to 
be  in  other  melanomas  (7).  Appreciable  amounts  of GM2  (fractions 99-107)  and  a 
number of minor components were also observed. Testing representative ganglioside 
fractions for AH  reactivity  showed  that  only one  series  of fractions  (140-150)  was 
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Fro.  1.  Serological reactivity of At1  serum  with  four  human  melanoma cell  lines:  SK-MEL-13 
(autologous AH melanoma)  ([3); SK-MEL-31  (O);  SK-MEL-29  (A); SK-MEL-28  (O). 
TABLE  I 
Serological Definition of the AH Antigenic System: Summary of Absorption Tests with Cells and Tissues 
and Inhibition Tests with Acidic Glycolipids 
Qualitative absorption tests with cells and tissues 
AH  + phenotype  AH- phenotype 
Melanoma  Melanoma  Other cancer cells 
SK-MEL-13, 23, 26, 27, 29,  SK-MEL-19, 21, 25, 28, 30, 40, 61,  Hep-2 (larynx), SK-SC-1  (squamous 
31, 36, 42, 44, 52, 57, 68, 73,  72, 78, 80, 83, 87, 93,  108  cell carcinoma), MOLT-4 (T cell 
75, 79, 80, 86, 88, 89, 91, 94,  Renal cancer  leukemia),  Raji  (B  cell  lym- 
95, 97,  100, 104, 106, 110, 112,  SK-RC-1, 2, 6, 7, 9,  11  phoma) 
113, MeWo  Bladder cancer  Fetal cells 
Astrocytoma  T-24, J-82  Skin fibroblasts 
SK-MG-AJ, AN, AS, BE, BOQ,  Colon cancer  WI-38 
BT, BU, U251-MG, U373-MG  HT-29,  SW-837,  SW-1083,  SW-  Retina (non-cuhured) 
Retinoblastoma  1222  Liver (non-cultured) 
WERI, Y-79  Cervical and ovarian cancer  Kidney (non-cultured) 
Neuroblastoma  HeLa, ME-180, SK-OV-3, RAOC  Normal adult cells 
SK-NMC, SK-N-SH  Breast cancer  Skin fibroblasts 
Meningioma  AIAb,  BT-20,  CAMA,  MCF-7,  (AX, AS, AT, BD) 
SK-MEN- 1  MDA-MBA-361  Liver (non-cultured) 
Chondrosarcoma  Lung cancer  Kidney (non-cultured) 
SK-CH-H, SK-CH-M  SK-LC-LL  EBV*-transformed B cells 
Neural tissue  Human erythrocytes (RBC)  AH, AV, BD, BT, CO, CZ, DE, DP. 
Fetal brain  A, B, AB, O  DY 
Adult brain  Xenogeneic cells 
VERO  (monkey  kidney),  CMS-4 
(chemically induced  mouse sar- 
coma), guinea pig kidney, spleen, 
liver; sheep  RBC,  mouse  RBC, 
rat RBC 
Melanoma 






Inhibition tests with acidic glycolipids  from cells and tissues 
Melanoma  Renal Cancer 
SK-MEL-21, 28  SK-RC-6, 7 
Colon Cancer  Cervical Cancer 
SW-1083  ME-I80 
Other Cells and Tissues  Xenogeneic Cells 
Raji (B cell lymphoma); A, B, AB,  Sheep RBC, Horse RBC 
RBC;  fetal  liver,  spleen;  adult 
liver, kidney, spleen 
* Epstein-Barr virus. 
with  GD2  in  thin  layer  chromatograms  (Fig.  2 B).  Because  of the  low  yield  of this 
ganglioside, a  complete structural analysis was not possible. 
Inhibition  Tests with Purified Gangliosides.  GM4,  GM3, GM2, GM], GD3, GD2, aDla, GDlb, 
and Gwlb were tested  for AH  inhibitory capacity  (Fig.  3).  Only GDz was found to be 
inhibitory.  Further inhibition  tests showed that  1/~g of Gm or fraction  140-150 from 
SK-MEL-13  was sufficient  for a  50% reduction in AH serum reactivity. WATANABE  ET  AL.  BRIEF  DEFINITIVE  REPORT  1887 
FIG.  2.  (A)  Fractionation of gangliosides from SK-MEL-13 cells by Iatrobead chromatography. 
Column fractions were assayed by thin-layer chromatography, and gangliosides were detected by 
resorcinol-HCl. Fractions  1-73  did not contain detectable gangliosides; fractions 74-85 contained 
GM3; fractions 86-122  are shown; fractions  123-150 contained minor ganglioside bands that were 
too weak to photograph. (B) Thin-layer chromatography of  AH-reactive fractions 140-150 (pooled) 
from latrobead chromatography of SK-MEL-13 gangliosides. Comparison with reference GD2 and 
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FIO.  3.  Inhibition of AH serum reactivity by purified gangliosides: unabsorbed serum (I~-'---O); 
GM1  (0---0);  GD2  (/k  A);  GM3  (A__ _A);  GD]a ((D  Q)); GM2  ((D---Q));  GD3  (1"1  [2]). 
Three other gangliosides (GM4, GDIb, and G'rlb) were also tested and found to be noninhibitory. 
Discussion 
Three classes of antigens have been distinguished in our analysis of the specificity 
of antibodies found in  patients  with  melanoma (3).  Antigens referred to as  class  1 
antigens show an absolute restriction to autologous melanoma cells, not being detected 
on any other malignant or normal cell type. Class 2 antigens, such as the AH antigen, 
are expressed by allogeneic as well as autologous melanoma and can be found on a 
limited range of normal cell types and other malignancies. Class 3 antigens are widely 
distributed on normal and malignant cells. 
From the pattern of cellular distribution, AH antigen has the characteristics of a 
differentiation antigen of cells of neuroectodermal origin. This also seems to be the 
case for GD2, which was originally identified as a  minor ganglioside in neural tissue 
(9, 10). GD2 represents 8% of the total ganglioside content in adult grey matter (9) and 
2% in human spinal cord (11). The fact that AH antigen was detected initially by an 
autologous antibody indicates that this cell surface component can be autoantigenic. 
AH antibody belongs to the IgM class and is preferentially reactive at 4°C; in  this 
respect it resembles other autoantibodies reactive with glycoconjugates, e.g., I, i (12), 1888  WATANABE ET Air.  BRIEF  DEFINITIVE REPORT 
Pr (13,  14), Gd (15),  lacto-N-neotetraose (16),  and P blood group (17). The stimulus 
for the production of AH antibody is unclear, particularly because AH antibody has 
also been detected in normal individuals (4) and astrocytoma patients (2). 
Irie (18)  and Gupta et al.  (19)  detected a  cell surface antigen designated OFA or 
OFA-1 that has features in common with AH. However, OFA-1 has been reported to 
be absent from adult brain and present on fibroblasts, the converse of AH distribution. 
To clarify the relation between OFA-1 and AH, we have recently exchanged reagents 
with Dr.  R.  Irie. The two antigens appear to be related serologically, because OFA 
typing antibody reacted with AH  + cells  but not with AH- cells  in a  panel of 42 cell 
types. This finding was surprising, as OFA-1 has been reported to be C/M insoluble 
(19) and relatively unstable at 4°C (20). 
We recently reported (7)  that another ganglioside, Gin, is a  prominent glycolipid 
in melanoma, in contrast to other cell types. As GD2 is derived from the addition of 
GalNAc  to  Gin,  it  will  be  interesting  to  determine  whether  there  is  an  inverse 
relationship  between  Gm  and  Go2  levels  in  melanomas  and  whether  there  is  a 
difference in  the specific transferase  catalyzing Gm biosynthesis in  AH  + and  AH- 
melanomas.  An  additional  point  has  to  do  with  the  protective effect  of antibody 
directed against AH/GD2 in patients with AH  + melanoma, a possibility that is raised 
by the unexpected favorable course of the initial melanoma patient with AH antibody. 
AH ganglioside appears to be weakly immunogenic, as indicated by the low frequency 
of antibody in melanoma patients and normal individuals. Moreover, vaccination of 
melanoma patients with AH  + melanoma cells did not elicit AH antibody, despite the 
inclusion of adjuvants such  as  BCG and  C.  parvum  in  the  vaccine  (21).  The weak 
immunogenicity of AH may be the result of several factors: (a)  its presence in brain 
and other neuroectodermally derived tissues (leading to variable degrees of tolerance), 
(b)  the  low  levels  of AH  ganglioside  in  melanoma  cells,  and  (c)  the  recognized 
difficulty of raising antibody to gangliosides (22).  Use of Goz or the oligosaccharide 
derived from GD2 coupled to an immunogenic carrier provides another approach to 
increasing the immune response to AH antigen in melanoma patients. 
Summary 
AH antigen,initially defined by an antibody present in a  melanoma patient,  is a 
cell  surface  antigen  found  on  ~65%  of melanoma  cell  lines.  Absorption  analysis 
indicates that AH is a differentiation antigen marking normal and malignant cells of 
neuroectodermal origin. The AH determinant has been found to be related to GD2 
ganglioside. 
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